WASHINGTON DC — The federal government spent the opening day of historic marijuana rescheduling hearings Monday making arguments that would have been almost unimaginable just a few years ago: cannabis has accepted medical use, carries lower abuse potential than drugs in Schedule I and II, and presents a lower overdose risk than opioids and alcohol.
Cannabis Industry Says It Has No Voice In Upcoming DEA Hearing That Could Affect Taxes, Research And Future Growth LANSING – Michigan's medical marijuana market has nearly vanished, generating just $322,350 in sales during May, according to the Michigan Cannabis Regulatory Agency. Yet a federal debate centered on marijuana's medical value could have sweeping consequences
NORML says agency misapplied federal law by excluding all supporters of cannabis reform from June 29 proceedings WASHINGTON DC - The National Organization for the Reform of Marijuana Laws (NORML) is accusing the Drug Enforcement Administration of creating a one-sided hearing process that could influence the future of federal marijuana policy and the financial outlook
WASHINGTON DC - The Drug Enforcement Administration has invited only opponents of marijuana reform to participate in a June 29 hearing that could influence the future of federal cannabis policy, a decision that is drawing criticism from legalization advocates, consumer groups and state-licensed marijuana businesses that were excluded from the proceedings. The hearing, scheduled to
DETROIT – A new legal challenge seeking to halt federal marijuana rescheduling is creating uncertainty for cannabis businesses nationwide, including in Michigan, where operators have been hoping federal reform would ease tax burdens and improve profitability. A coalition led by the National Drug and Alcohol Screening Association and a cannabis-focused pharmaceutical company has asked a
Michigan still dominates cannabis sales and attracts thousands of out-of-state shoppers every week. But Ohio's higher prices, stronger profit margins and expanding adult-use market could position it to benefit more from upcoming federal cannabis reforms. ANN ARBOR - Michigan sells more cannabis than Ohio. Ohio makes more money. That simple reality may shape the future
COLUMBUS - A shift in federal marijuana policy could give Ohio’s cannabis industry a financial edge—and potentially draw more customers across the border from Michigan. The U.S. Department of Justice has moved state-licensed medical marijuana from Schedule I to Schedule III, easing federal restrictions for part of the industry. It’s not full legalization. But for operators,
WASHINGTON DC - A major federal marijuana policy shift announced April 23 is much narrower than our earlier headlines suggested—and for Michigan’s $3 billion recreational cannabis market, the immediate impact is very limited. The U.S. Department of Justice, working with the Drug Enforcement Administration, has moved to reclassify state-licensed medical marijuana as a less dangerous
